Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study F. Valenzuela, C. de la Cruz Fernandez, R.L. Galimberti, S. Gürbüz, M. McKean-Matthews, L. Goncalves, R. Romiti

Psoriasis Severity, Health-Related Quality of Life, Work Productivity, and Activity Impairments Among Patients With Moderate to Severe Psoriasis Receiving Systemic Treatment: Real-World Data From Clinical Practice in Spain E. Daudén, D. Vidal, A. Romero, M.T. Bordel, R. Rivera, J. Márquez, E. Zamora, L. Martinez, M.J. Ocaña, C. Vila, P. Iribarren, N. Corona, A. Zulaica

Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study A. Martorell-Calatayud, S. Santos-Alarcón, A. Sahuquillo-Torralba, R. Rivera-Díaz, I. Belinchón-Romero, D. Ruiz-Genao, A. Romero-Maté, R. Ruiz-Villaverde, M. Ferran-Farrés, F. Gallardo-Hernández, M. Almenara-Blasco, J.A. Suarez-Perez, Á. González-Cantero, E. Martínez-Lorenzo, J.M. Fernández-Armenteros, E. del Alcázar-Viladomiu, J. García-Latasa, V. Rocamora-Durant, M. Ara-Martín, A. Mateu-Puchades, M. Llamas-Velasco, E. Vilarrasa, M. Velasco-Pastor, P. De la Cueva, J.M. Carrascosa, J. Magdaleno-Tapial